Skip to main content
Caplight Logo









Concr

Concr

Private
LondonHealthcare & Life Scienceshttps://concr.co/

Last Round

Grant

Feb 9, 2024

Total Funding Raised

$4.66M

Company Overview

Concr is a techbio company that provides a predictive modelling platform, FarrSight®, to enhance confidence and foresight about the therapeutic efficacy of existing and emerging cancer drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

precision oncologydigital twinspredictive modelingclinical trial simulationBayesian AItechbiobiomarker discoverydrug developmentin silico trialsdigital histopathologycomputational biologyAI drug discoverytranslational medicinecloud-native platformpatient-level modeling

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Concr Comparables

Compare Concr with similar companies based on industry and business-model similarity.

Concr comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VeriSIM Life
81%
InSilicoTrials Technologies
80%
Epigene Labs
79%

Concr Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 9, 2024
SeedNov 29, 2023
SeedMar 31, 2023

Key People

Founding team and executive leadership

Irina Babina

Chief Executive Officer

Executive Team

Conor Woolfson

Chief Financial Officer

Executive Team

Emre Misirlioglu

Chief Operating Officer

Executive Team

Concr Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors increased 85% MoM.

  • Feb 9, 2024

    $1.26M grant awarded by Innovate UK

Concr Filings

Explore SEC and related filing metadata, where available.

Concr filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Concr's valuation, stock price, and market status.

Is Concr a public or private company?

Concr is a private company.

What is the current stock price of Concr?

Concr is a private company with no public stock price. No recent secondary market data is available.

How much is Concr worth (valuation)?

Valuation information for Concr is not publicly available.

Can I buy Concr stock?

Concr shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Concr's last funding round?

Concr's most recent funding round was Grant on February 9, 2024.

Who are the main investors in Concr?

Key investors in Concr include Cambridge Enterprise.

Will Concr IPO soon?

No public IPO plans have been announced for Concr.

How can I track Concr secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Concr's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range9
Year Founded2018
Last FundingFeb 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?